Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSTs for CMV and ADV Infections Post-HCT
NCT05664126Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of viral-specific T-cells in cytomegalovirus infection (CMV) and adenovirus infection (2 cohorts), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Degree of reduction of CMV and/or ADV viral load at 4 weeks. Started Aug 2023; status: recruiting.
02
Drugs
viral-specific T-cells
03
Conditions
cytomegalovirus infection (CMV)adenovirus infection
Beyond the preview
Go deeper on NCT05664126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664126.